Inflammatory Bowel Disease News and Research RSS Feed - Inflammatory Bowel Disease News and Research

Inflammatory bowel disease (IBD) is an ongoing or chronic health problem that causes inflammation and swelling in the digestive tract. The irritation causes bleeding sores called ulcers to form along the digestive tract. This in turn can cause crampy, abdominal pain and severe bloody diarrhea.

There are two main types of inflammatory bowel disease: ulcerative colitis (UC) and Crohn's disease (CD). The diseases are very similar. In fact, doctors often have a hard time figuring out which type of IBD a person has. The main difference between UC and CD is the area of the digestive tract they affect. CD can occur along the entire digestive tract and spread deep into the bowel wall. In contrast, UC usually only affects the top layer of the large intestine (colon) and rectum. Medicine can control the symptoms of IBD in most women. But for people who have severe IBD, surgery is sometimes needed. Over the course of a person's life, the symptoms of IBD often come and go. With close monitoring and medicines, most people with IBD lead full and active lives.

Vaccine against H. pylori infection is within reach

Researchers from the University of Rhode Island are championing a recent breakthrough in the laboratory with hopes it could lead to a vaccine against the pathogen responsible for stomach cancer and to therapeutics for inflammatory diseases. [More]

Studies identify 2 genes highly associated with IBD

Inflammatory Bowel Disease (IBD), a group of chronic inflammatory disorders of the intestine that result in painful and debilitating complications, affects over 1.4 million people in the U.S., and while there are treatments to reduce inflammation for patients, there is no cure. [More]
New genetic evidence strengthens link between role of dietary fats with colon cancer progression

New genetic evidence strengthens link between role of dietary fats with colon cancer progression

Scientists have shown new genetic evidence that could strengthen the link between the role of dietary fats with colon cancer progression. [More]
New study identifies potential target for colorectal cancer treatment

New study identifies potential target for colorectal cancer treatment

A new study identifies a molecule that is a probable driving force in colorectal cancer and suggests that the molecule could be an important target for colorectal cancer treatment and a valuable biomarker of tumor progression. [More]
Researchers show Elafin protein plays key role against inflammatory reaction typical of celiac disease

Researchers show Elafin protein plays key role against inflammatory reaction typical of celiac disease

Scientists from INRA and INSERM (France) in collaboration with scientists from McMaster University (Canada) and the Ecole polytechnique fédérale of Zurich (Switzerland) have shown that Elafin, a human protein, plays a key role against the inflammatory reaction typical of celiac disease (gluten intolerance). [More]

New insights provide novel therapeutic approach against cancer

A major discovery that brings a new drug target to the increasingly exciting landscape of cancer immunotherapy was published yesterday by researchers from La Jolla Institute for Allergy and Immunology and their collaborators from other institutes. [More]
Ulcerative colitis control: an interview with Dr Paul Robinson, Medical Director, MSD UK

Ulcerative colitis control: an interview with Dr Paul Robinson, Medical Director, MSD UK

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD), which means there is chronic inflammation and ulceration in the lining of the digestive tract, usually in the large intestine. [More]
ASU scientist selected as 2014 recipient of Lifetime Achievement Award

ASU scientist selected as 2014 recipient of Lifetime Achievement Award

Roy Curtiss III, a scientist at the Biodesign Institute at Arizona State University, has been selected as the 2014 recipient of the Lifetime Achievement Award from the American Society for Microbiology. [More]

Study suggests effective therapeutics for IBD may hinge on targeting GM-CSF axis

​The protein GM-CSF plays a critical role in maintaining immune tolerance in the gut, with defects in the protein increasing the susceptibility to inflammatory bowel diseases (IBD), according to a new mouse study by a team of researchers from the Icahn School of Medicine at Mount Sinai. [More]
Gut bacteria and blood cell development relationship helps immune system fight infection

Gut bacteria and blood cell development relationship helps immune system fight infection

The human relationship with microbial life is complicated. At almost any supermarket, you can pick up both antibacterial soap and probiotic yogurt during the same shopping trip. [More]

SCCA experts develop helpful tool to simplify colon cancer prevention, screening guidelines

Colon cancer will take more than 50,000 American lives in 2014 making it the second leading cause of cancer-related deaths, according to the American Cancer Society. [More]
Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics, Inc. today announced fourth quarter and full-year 2013 financial results. For the three months ended December 31, 2013, Safeguard's net income was $24.0 million, or $1.10 per share, compared to net loss of $10.8 million, or $0.51 per share for the same period in 2012. For the year ended December 31, 2013, Safeguard's net loss was $35.5 million, or $1.66 per share, compared to $39.4 million, or $1.88 per share for the same period in 2012. [More]
UCLA experts offer tips to help protect colon health

UCLA experts offer tips to help protect colon health

With colorectal cancer the second leading cause of cancer death, it's a great time to take a look at the health of your colon. [More]

Altheus Therapeutics completes dosing of ZA201 in Phase 2 trial of Zoenasa for ulcerative colitis

Altheus Therapeutics, Inc., announced completion of dosing in ZA201, a double-blind, active-controlled Phase 2 trial evaluating the efficacy and safety of Zoenasa® Rectal Gel versus mesalamine enema in 120 patients with left-sided ulcerative colitis. [More]
Researchers identify new type of regulatory blood cells that can combat brain inflammation

Researchers identify new type of regulatory blood cells that can combat brain inflammation

Hyperactivity of our immune system can cause a state of chronic inflammation. If chronic, the inflammation will affect our body and result in disease. In the devastating disease multiple sclerosis, hyperactivity of immune cells called T-cells induce chronic inflammation and degeneration of the brain. Researchers at BRIC, the University of Copenhagen, have identified a new type of regulatory blood cells that can combat such hyperactive T-cells in blood from patients with multiple sclerosis. By stimulating the regulatory blood cells, the researchers significantly decreased the level of brain inflammation and disease in a biological model. [More]
Elusive progenitor cells that give rise to ILCs identified in fetal liver and bone marrow of mice

Elusive progenitor cells that give rise to ILCs identified in fetal liver and bone marrow of mice

The elusive progenitor cells that give rise to innate lymphoid cells-a recently discovered group of infection-fighting white blood cells-have been identified in fetal liver and adult bone marrow of mice, researchers from the University of Chicago report early online in the journal Nature. [More]

Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the company was awarded U.S. Patent No. 8,647,626, entitled "Compositions Comprising TNF-specific Antibodies for Oral Delivery." [More]
Telephone communication in IBD care helps to identify patients at risk of high-cost medical interventions

Telephone communication in IBD care helps to identify patients at risk of high-cost medical interventions

A comprehensive analysis of patient telephone records at an inflammatory bowel disease (IBD) clinic revealed that 15 percent of patients account for half of all calls to the clinic. Forty-two percent of frequent-caller patients also were seen in the emergency department or hospitalized within the following year. [More]
Blood disorder medicines could be used for treating stomach and bowel cancer

Blood disorder medicines could be used for treating stomach and bowel cancer

Stomach and bowel cancer, two of the most common cancers worldwide, could be treated with a class of medicines that are currently used to treat a blood disorder, a Melbourne research team has discovered. [More]

Altheus Therapeutics receives patent for oral combination therapy for treating inflammatory bowel disease

Altheus Therapeutics, Inc. announced the USPTO has allowed patent 8,629,127 B2 covering the oral pharmaceutical composition 5-ASA (5-aminosalicylic acid) and NAC (N-acetylcysteine). [More]